Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome

被引:210
作者
Marshall, RP [1 ]
Bellingan, G [1 ]
Webb, S [1 ]
Puddicombe, A [1 ]
Goldsack, N [1 ]
McAnulty, RJ [1 ]
Laurent, GJ [1 ]
机构
[1] Royal Free & UCL, Sch Med, Rayne Inst, Ctr Resp Res, London, England
关键词
D O I
10.1164/ajrccm.162.5.2001061
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The fibroproliferative phase of acute respiratory distress syndrome (ARDS) has traditionally been regarded as a late event but recent studies that suggest increased lung collagen turnover within 24 h of diagnosis challenge this view. We hypothesized that fibroproliferation is initiated early in ARDS, characterized by the presence of fibroblast growth factor activity in the lung and would relate to clinical outcome. Patients fulfilling American/European Consensus Committee criteria for ARDS and control patients ventilated for non-ARDS respiratory failure underwent bronchoalveolar lavage (BAL) and serum sampling within 24 h of diagnosis and again at 7 d. The ability of BAL fluid (BALF) to stimulate human lung fibroblast proliferation in vitro was examined in relation to concentrations of N-terminal peptide for type III procollagen (N-PCP-III) in BALF/serum and clinical indices. At 24 h, ARDS lavage fluid demonstrated potent mitogenic activity with a median value equivalent to 70% (range 31-164) of the response to serum, and was significantly higher than control lavage (32% of serum response, range 11-42; p < 0.05). At 24 h, serum N-PCP-III concentrations were elevated in the ARDS group compared with control patients (2.8 U/ml; range 0.6-14.8 versus 1.1 U/ml; range 0.4-3.7, p < 0.0001) as were BALF N-PCP-III concentrations (2.9 U/ml; range 0.6-11.4 versus 0.46 U/ml; range 0.00-1.63, p < 0.01). In addition, BALF N-PCP-III concentrations at 24 h were significantly elevated in nonsurvivors of ARDS compared with survivors (p < 0.05). At 7 d, the mitogenic activity remained elevated in the ARDS group compared with control (p < 0.05) and was also significantly higher in ARDS nonsurvivors compared with survivors (67%; range 45-120 versus 31%; range 16-64 p < 0.05). These data are consistent with the hypothesis that fibroproliferation is an early response to lung injury and an important therapeutic target.
引用
收藏
页码:1783 / 1788
页数:6
相关论文
共 42 条
[21]   A NEW SIMPLIFIED ACUTE PHYSIOLOGY SCORE (SAPS-II) BASED ON A EUROPEAN NORTH-AMERICAN MULTICENTER STUDY [J].
LEGALL, JR ;
LEMESHOW, S ;
SAULNIER, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (24) :2957-2963
[22]  
LENNQUIST S, 1985, ACTA CHIR SCAND, P104
[23]   ATTENUATION OF PULMONARY FIBROSIS IN MICE BY AMINOPHYLLINE [J].
LINDENSCHMIDT, RC ;
WITSCHI, H .
BIOCHEMICAL PHARMACOLOGY, 1985, 34 (24) :4269-4273
[24]   INTRATRACHEAL VERSUS INTRAVENOUS ADMINISTRATION OF BLEOMYCIN IN MICE - ACUTE EFFECTS [J].
LINDENSCHMIDT, RC ;
TRYKA, AF ;
GODFREY, GA ;
FROME, EL ;
WITSCHI, H .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1986, 85 (01) :69-77
[25]   Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland [J].
Luhr, OR ;
Antonsen, K ;
Karlsson, M ;
Aardal, S ;
Thorsteinsson, A ;
Frostell, CG ;
Bonde, J .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (06) :1849-1861
[26]   Elevated transforming growth factor-α levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome [J].
Madtes, DK ;
Rubenfeld, G ;
Klima, LD ;
Milberg, JA ;
Steinberg, KP ;
Martin, TR ;
Raghu, G ;
Hudson, LD ;
Clark, JG .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (02) :424-430
[27]   Indomethacin suppresses the anti-proliferative effects of transforming growth factor-beta isoforms on fibroblast cell cultures [J].
McAnulty, RJ ;
HernandezRodriguez, NA ;
Mutsaers, SE ;
Coker, RK ;
Laurent, GJ .
BIOCHEMICAL JOURNAL, 1997, 321 :639-643
[28]  
MCANULTY RJ, 1995, EXP NEPHROL, V3, P96
[29]  
Meduri GU, 1998, AM J RESP CRIT CARE, V158, P1432
[30]   The role of the host defence response in the progression and outcome of ARDS: Pathophysiological correlations and response to glucocorticoid treatment [J].
Meduri, GU .
EUROPEAN RESPIRATORY JOURNAL, 1996, 9 (12) :2650-2670